Sandrine Poglio

Sandrine Poglio

Auto-generated profile, based on publicly available information

Sandrine Poglio

Bordeaux Institute of Oncology, Unité Mixte de Recherche 1312, INSERM, University of Bordeaux, Team 5, Bordeaux, France

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
22 January 2021 in Blood Advances
Verified
Journal Article
Open access
PDF file
LFLucine Fahy
Lucine Fahy
JCJulien Calvo
Julien Calvo
SCSara Chabi
Sara Chabi
LRLaurent Renou
Laurent Renou
CMCharly Le Maout
Charly Le Maout
BUBenjamin Uzan
Benjamin Uzan
Resistance to chemotherapy, a major therapeutic challenge in the treatment of T-cell acute lymphoblastic leukemia (T-ALL), can be driven by interactions between leukemic cells and the microenvironment that promote survival of leukemic cells. The bone marrow, an important leukemia niche, has low oxygen partial pressures that highly participate in the regulation of normal hematopoiesis. Here we show that hypoxia inhibits T-ALL cell growth by slowing down cell cycle progression, decreasing mitochondria activity, and increasing glycolysis, making them less sensitive to antileukemic drugs and preserving their ability to initiate leukemia after treatment. Activation of the mammalian target of rapamycin (mTOR) was diminished in hypoxic leukemic cells, and treatment of T-ALL with the mTOR inhibitor rapamycin in normoxia mimicked the hypoxia effects, namely decreased cell growth and increased quiescence and drug resistance. Knocking down (KD) hypoxia-induced factor 1α (HIF-1α), a key regulator of the cellular response to hypoxia, antagonized the effects observed in hypoxic T-ALL and restored chemosensitivity. HIF-1α KD also restored mTOR activation in low O2 concentrations, and inhibiting mTOR in HIF1α KD T-ALL protected leukemic cells from chemotherapy. Thus, hypoxic niches play a protective role of T-ALL during treatments. Inhibition of HIF-1α and activation of the mTORC1 pathway may help suppress the drug resistance of T-ALL in hypoxic niches.

26 October 2020 in Leukemia
Verified
Journal Article
Open access
PDF file
SPSandrine Poglio
Sandrine Poglio
MPMartina Prochazkova-Carlotti
Martina Prochazkova-Carlotti
FCFloriane Cherrier
Floriane Cherrier
AGAudrey Gros
Audrey Gros
ELElodie Laharanne
Elodie Laharanne
JMJean-Philippe Merlio
Jean-Philippe Merlio
Sézary Syndrome (SS) is a rare aggressive epidermotropic cutaneous T-cell lymphoma (CTCL) defined by erythroderma, pruritis, and a circulating atypical CD4 + T-cell clonal population. The diversity of Sézary cell (SC) phenotype and genotype may reflect either plasticity or heterogeneity, which was difficult to evaluate dynamically until the achievement of long-term SC expansion. Therefore, we developed six defined culture conditions allowing for the expansion of SC defined by their phenotype and monoclonality in four of seven SS cases. Engraftment of SC through the intrafemoral route into immunodeficient NOD.Cg-Prkdc(scid)Il2rg(tm1Wjll)/SzJ (NSG) mice was achieved in 2 of 14 SS cases. Secondary xenograft by percutaneous injection mimicked most of the features of SS with dermal infiltration, epidermotropism, and blood spreading. These models also allowed assessing the intra-individual heterogeneity of patient SC. Subclones sharing the same TCR gene rearrangement evolved independently according to culture conditions and/or after xenografting. This clonal selection was associated with some immunophenotypic plasticity and limited genomic evolution both in vitro and in vivo. The long-term amplification of SC allowed us to develop eight new SC lines derived from four different patients. These lines represent the cell of origin diversity of SC and provide new tools to evaluate their functional hallmarks and response to therapy.

16 July 2022 in Journal of Investigative Dermatology
Verified
Journal Article
Open access
SPSara Peru
Sara Peru
MPMartina Prochazkova-Carlotti
Martina Prochazkova-Carlotti
FCFloriane Cherrier
Floriane Cherrier
JVJoanne Velazquez
Joanne Velazquez
RERICHARD Elodie
RICHARD Elodie
SPSandrine Poglio
Sandrine Poglio
Cutaneous T-cell lymphoma (CTCL) such as Sézary syndrome or mycosis fungoides corresponds to an abnormal infiltration of T lymphocytes in the skin. CTCL cells have a heterogeneous phenotype and express cell adhesion molecules such as cutaneous lymphocyte antigen (CLA) supporting skin homing. The use of a mAb (HECA-452) against CLA significantly decreased transendothelial migration and survival of CTCL cells from patient samples and My-La cell line. The decrease of CLA expression by inhibition of its maturation enzyme, ST3 β-galactoside α-2,3-sialyltransferase 4, also impaired CTCL cell migration, proliferation, and survival. We confirmed in vivo that treatment with anti-CLA mAb decreased the tumorigenicity as well as dissemination of CTCL cells in different tissues compared with the control group. Our findings provide evidence of the involvement of CLA in CTCL cell migration and survival, supporting that CLA inhibition could represent an actionable therapy in patients with CTCL.

12 May 2016 in Oncotarget
Verified
Journal Article
Open access
PDF file
SPSandrine Poglio
Sandrine Poglio
DLDaniel Lewandowski
Daniel Lewandowski
JCJulien Calvo
Julien Calvo
ACAurélie Caye
Aurélie Caye
AGAudrey Gros
Audrey Gros
FPFrançoise Pflumio
Françoise Pflumio
Speed of leukemia development and genetic diversity in xenograft models of T cell acute lymphoblastic leukemia Speed of leukemia development and genetic diversity in xenograft models of T cell Acute Lymphoblastic Leukemia

26 October 2018 in Cancers
Verified
Journal Article
Open access
PDF file
SLSimon Latour
Simon Latour
IMIsabelle Mahouche
Isabelle Mahouche
FCFloriane Cherrier
Floriane Cherrier
LALamia Azzi-Martin
Lamia Azzi-Martin
VVValérie Velasco
Valérie Velasco
LBLaurence Bresson-bepoldin
Laurence Bresson-bepoldin
Ca2+ release-activated Ca2+ channels, composed of Orai1 and STIM1 (stromal interaction molecule 1) proteins, are the main Ca2+ entry mechanism in lymphocytes. Their role in cell migration and metastasis is demonstrated in solid cancers but it remains elusive in malignant hemopathies. Diffuse large B cell lymphoma (DLBCL) is characterized by the dissemination of neoplastic B cells throughout the organism which is under the control of chemokines such as Stromal Derived Factor 1 (SDF-1) and its receptor CXCR4. CXCR4 activation triggers a complex intracellular signaling including an increase in intracellular Ca2+ concentration whose role is still unclear. Using pharmacological and genetic approaches, we revealed that STIM1 and Orai1 were responsible for Ca2+ influx induced by SDF-1. Furthermore, we provide in vitro and in vivo evidence that they are necessary for basal or SDF-1-induced DLBCL cell migration which is independent of Ca2+ entry. We identify that they act as effectors coupling RhoA and ROCK dependent signaling pathway to MLC2 phosphorylation and actin polymerization. Finally, we revealed an alteration of Orai1 and STIM1 expression in extra-nodal DLBCL. Thus, we discovered a novel Ca2+-independent but Orai1 and STIM1-dependent signaling pathway involved in basal and CXCR4 dependent cell migration, which could be relevant for DLBCL physiopathology.

8 February 2023 in Genes
Verified
Journal Article
Open access
PDF file
JRJoana Ropio
Joana Ropio
MPMartina Prochazkova-Carlotti
Martina Prochazkova-Carlotti
RBRui Batista
Rui Batista
APAna Pestana
Ana Pestana
Alain CHEBLYAlain CHEBLY
Alain CHEBLY
ECEdith Chevret
Edith Chevret
As a major cancer hallmark, there is a sustained interest in understanding the telomerase contribution to carcinogenesis in order to therapeutically target this enzyme. This is particularly relevant in primary cutaneous T-cell lymphomas (CTCL), a malignancy showing telomerase dysregulation with few investigative data available. In CTCL, we examined the mechanisms involved in telomerase transcriptional activation and activity regulation. We analyzed 94 CTCL patients from a Franco-Portuguese cohort, as well as 8 cell lines, in comparison to 101 healthy controls. Our results showed that not only polymorphisms (SNPs) located at the promoter of human telomerase reverse transcriptase (hTERT) gene (rs2735940 and rs2853672) but also an SNP located within the coding region (rs2853676) could influence CTCL occurrence. Furthermore, our results sustained that the post-transcriptional regulation of hTERT contributes to CTCL lymphomagenesis. Indeed, CTCL cells present a different pattern of hTERT spliced transcripts distribution from the controls, mostly marked by an increase in the hTERT β+ variants proportion. This increase seems to be associated with CTCL development and progression. Through hTERT splicing transcriptome modulation with shRNAs, we observed that the decrease in the α-β+ transcript induced a decrease in the cell proliferation and tumorigenic capacities of T-MF cells in vitro. Taken together, our data highlight the major role of post-transcriptional mechanisms regulating telomerase non canonical functions in CTCL and suggest a new potential role for the α-β+ hTERT transcript variant.